Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 4/20 | 0.33 |
| ▸ | FPR2 | P25090 | 4/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513439 | 0.92 | KMT2A (0.48) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL1626503 | 0.91 | RAB9A (0.46) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL3680500 | 0.91 | RAB9A (0.46) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL4991711 | 0.90 | RAB9A (0.36) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL11339800 | 0.85 | KMT2A (0.41) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL11332040 | 0.84 | KMT2A (0.39) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL21485042 | 0.80 | KMT2A (0.47) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL1628845 | 0.77 | KMT2A (0.49) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL138215 | 0.75 | THRB (0.41) | KMT2ARAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL9470924 | 0.74 | ALDH1A1 (0.33) | KMT2AALDH1A1KDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120553-B1 | PRODUCTION OF SOLID SOLUTIONS OF PESTICIDES BY SHORT TERM SUPERHEATING AND RAPID DRYING | BASF SE (DE) | 2014-05-28 | — | — | EP | disclosed |
| EP-2120553-A2 | PRODUCTION OF SOLID SOLUTIONS OF PESTICIDES BY SHORT TERM SUPERHEATING AND RAPID DRYING | BASF SE (DE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080167189-A1 | Polymer Compositions and Their Use in the Production of Active or Effective Ingredient Compositions | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008065051-A2 | PRODUCTION OF SOLID SOLUTIONS OF PESTICIDES BY SHORT TERM SUPERHEATING AND RAPID DRYING | BASF SE (DE) | 2008-06-05 | — | — | WO | disclosed |
| EP-1851262-A1 | POLYMER COMPOSITIONS AND THEIR USE IN THE PRODUCTION OF ACTIVE OR EFFECTIVE INGREDIENT COMPOSITIONS | BASF AKTIENGESELLSCHAFT (DE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006084680-A1 | POLYMER COMPOSITIONS AND THEIR USE IN THE PRODUCTION OF ACTIVE OR EFFECTIVE INGREDIENT COMPOSITIONS | BASF AKTIENGESELLSCHAFT (DE) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167189-A1 | Polymer Compositions and Their Use in the Production of Active or Effective Ingredient Compositions | GANC, PHOSPHO1, PGLS | KMT2A 3150/4885RAB9A 3121/4885ALDH1A1 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.